// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























7277 Abstracts

Optical coherence tomography-guided optimal bioresorbable vascular scaffold implantation informs subsequent implantation without intravascular imaging: further evidence for a learning curve?

Vincent Flore - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

Everolimus

Two-year clinical outcomes of patients treated with overlapping ABSORB scaffolds: An Analysis of the ABSORB EXTEND Single Arm Study

Jose Costa Jr - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Everolimus

Thirty-day Outcome Following Polymeric Bioresorbable Scaffold Implantation in 347 STEMI Patients Enrolled in the Multicenter Registro Absorb Italiano (RAI Registry)

Alfonso Ielasi - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Everolimus

6 year experience with the Absorb bioresorbable vascular scaffold: The Maasstad Absorb Registry

George Vlachojannis - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Everolimus

Risk and timing of clinical events according to diabetic status of patients treated with Everolimus-Eluting Bioresorbable Vascular Scaffolds vs. Everolimus-Eluting stent: 2-Year results from a propensity score matched comparison of ABSORB EXTEND and SPIRIT trials

Carlos Campos - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

Everolimus

Long-term clinical outcomes after implantation of everolimus-eluting bioresorbable vascular scaffold in patients with acute myocardial infarction. 24-month clinical follow-up of the BVS STEMI First Study

Mariusz Tomaniak - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Everolimus

Two-year outcomes of patients with acute coronary syndrome versus stable coronary disease undergoing bioresorbable scaffold implantation

Jens Wiebe - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Everolimus

Absorb Bioresorbable Vascular Scaffolds vs. XIENCE Everolimus-Eluting Stents: Are Clinical Outcomes Different for Men and Women?

Dean Kereiakes - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Everolimus

Bioresorbable vascular scaffold in chronic total coronary artery occlusions: results from the RAI registry

Bruno Loi - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Everolimus

Usefulness of a scoring system for predicting adverse cardiovascular events in patients undergoing everolimus-eluting bioresorbable scaffolds implantation: the PSP score

Luis Ortega-Paz - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Everolimus

6 year clinical outcomes after Absorb bioresorbable scaffold implantation in small vessel: The Maasstad Absorb Registry

Valeria Paradies - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Everolimus

Bioresorbable vascular scaffold technology for small vessel coronary artery disease: results from the Italian multicenter RAI Registry

Giulia Masiero - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

Everolimus

Comparison of Neointimal Coverage Patterns between Biodegradable Vascular Stents and Drug Eluting Stents using Optical Coherence tomography: A Meta-Analysis

Pradyumna Agasthi - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

N/A

Bioresorbable Coronary Devices in Clinical Practice: 6-month Results of the Prospective REPARA Registry

Felipe Hernandez - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Clopidogrel bisulfate

Safety, feasibility and performance of the first 300 everolimus-eluting bioresorbable scaffold PCI in an all-comers population with ischemic heart disease

Arif Al Nooryani - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Everolimus

IMPACT OF GENDER ON 1-YEAR OUTCOMES AFTER IMPLANTATION OF BIORESORBABLE DRUG-ELUTING SCAFFOLDS

Moritz Baquet - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

N/A

Implantation of Absorb Bioresorbable Vascular Scaffolds in Small Vessel Coronary Artery Disease: Long-term follow-up

Babu Ezhumalai - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Everolimus

Multi-Center, Post-marketing Evaluation of the Elixir DESolve Novolimus Eluting Bioresorbable Coronary Stent System: 6-month Results from the DESolve PMCF Study

Holger Nef - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Outcomes After Bailout Stenting with Absorb BVS or XIENCE: Meta-analysis of Randomized Trials

Stephen Ellis - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Everolimus

Increased incidence of revascularization in diabetic patients treated with the ABSORB everolimus-eluting bioresorbable scaffold: 24-months clinical results

Robin Kraak - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

Everolimus

Copyright © 2026. QuantiNova All rights reserved